Literature DB >> 20686822

Venous thromboembolism (VTE) in hospitalized cancer patients: prophylaxis failure or failure to prophylax!

Hikmat Abdel-Razeq1, Faisal Albadainah, Shadi Hijjawi, Asem Mansour, Imad Treish.   

Abstract

Cancer patients are at higher risk for venous thromboembolism (VTE). Anticoagulants, when used for prophylaxis, had successfully reduced the incidence of VTE in high risk patients. Nevertheless, many registry studies have shown low compliance rate with published prophylaxis guidelines. From January 2004 through June 2008, hospital database was searched for all discharge diagnoses of cancer with deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Prophylaxis rate for the whole group and for subgroups in relation to recent hospitalization, duration of cancer diagnosis and number of other coexisting risk factors were studied. Two hundred patients were identified; majority (91.8%) had advanced-stage cancer at time of VTE diagnosis. In addition to cancer, many patients had multiple coexisting risk factors for VTE with 137 (68.5%) patients had at least three while 71 (35.5%) had four or more. Overall, 111(55.5%) patients developed lower-extremity DVT while 52 (26%) patients developed PE, other sites accounted for 18%. Majority of the patients (72%) had VTE diagnosed within the first 12 months following cancer diagnosis. Almost three quarters of the patients (73.5%) had not received any antecedent prophylaxis. Prophylaxis rate was 23% among patients with ≥ 3 risk factors and 50% among the highest risk group with ≥ 5 risk factors. Based on our findings, majority of VTE in cancer patients occurred due to failure to offer prophylaxis, minority were due to prophylaxis failure. Meticulous quality improvement programs should be established to emphasize the importance of implementing more intensive prophylaxis among high-risk cancer patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20686822     DOI: 10.1007/s11239-010-0509-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  19 in total

1.  Variation in relative risk of venous thromboembolism in different cancers.

Authors:  P A Thodiyil; A K Kakkar
Journal:  Thromb Haemost       Date:  2002-06       Impact factor: 5.249

2.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.

Authors:  John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-06-10

3.  Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.

Authors:  Victor F Tapson; Hervé Decousus; Mario Pini; Beng H Chong; James B Froehlich; Manuel Monreal; Alex C Spyropoulos; Geno J Merli; Rainer B Zotz; Jean-François Bergmann; Ricardo Pavanello; Alexander G G Turpie; Mashio Nakamura; Franco Piovella; Ajay K Kakkar; Frederick A Spencer; Gordon Fitzgerald; Frederick A Anderson
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

4.  The long-term clinical course of acute deep venous thrombosis.

Authors:  P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

5.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

6.  The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly.

Authors:  W D Kniffin; J A Baron; J Barrett; J D Birkmeyer; F A Anderson
Journal:  Arch Intern Med       Date:  1994-04-25

7.  High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).

Authors:  Cihan Ay; Ralph Simanek; Rainer Vormittag; Daniela Dunkler; Guelay Alguel; Silvia Koder; Gabriela Kornek; Christine Marosi; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

8.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

9.  Prevention of deep vein thrombosis in medical patients by low-dose heparin.

Authors:  J J Belch; G D Lowe; A G Ward; C D Forbes; C R Prentice
Journal:  Scott Med J       Date:  1981-04       Impact factor: 0.729

10.  Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.

Authors:  Susan R Kahn; Akbar Panju; William Geerts; Graham F Pineo; Louis Desjardins; Alexander G G Turpie; Stanislav Glezer; Lehana Thabane; Rolf J Sebaldt
Journal:  Thromb Res       Date:  2006-03-03       Impact factor: 3.944

View more
  6 in total

Review 1.  Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?

Authors:  Hikmat Abdel-Razeq; Asem Mansour
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

Review 2.  Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR).

Authors:  Whitney D Maxwell; Charles L Bennett
Journal:  Semin Thromb Hemost       Date:  2012-10-30       Impact factor: 4.180

3.  Management of perioperative acute massive pulmonary embolism: A case series.

Authors:  Ji-Yoon Kim; Young-Seok Lee; Hyun Oh Park; Il Woo Shin
Journal:  Clin Case Rep       Date:  2021-03-28

4.  Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!

Authors:  Hikmat Abdel-Razeq; Asem Mansour; Hazem Abdulelah; Anas Al-Shwayat; Mohammad Makoseh; Mohammad Ibrahim; Mahmoud Abunasser; Dalia Rimawi; Abeer Al-Rabaiah; Rozan Alfar; Alaa' Abufara; Alaa Ibrahim; Anas Bawaliz; Yousef Ismael
Journal:  Thromb J       Date:  2018-03-01

5.  Incidence and Determinants of Chemotherapy Associated Thromboembolic Events among Ethiopian Patients Treated for Solid Malignancy: A Retrospective Cross-Sectional Study.

Authors:  Abdella Birhan Yabeyu; Shemsu Umer Hussen; Wondemagegnhu Tigneh; Atalay Mulu Fentie
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

6.  The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients.

Authors:  Hikmat Abdel-Razeq; Mohammad Ma'koseh; Rashid Abdel-Razeq; Rula Amarin; Alaa Abufara; Razan Mansour; Mohammad Manasrah; Mohammad Al-Rwashdeh; Rayan Bater
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.